Buzz: Ariad soars on reports that Baxalta has come calling about a buyout

John Carroll

Shire has been quiet since making its unwelcomed $ 30 billion bid to acquire public earlier this month. But evidently isn't waiting for the next step to play out in that dance. Bloomberg is reporting this afternoon that Baxalta is hunting for an acquisition around the $ 2 billion mark that would add to its hematology pipeline.

FierceBiotech News

Share This Post

Related Articles

Leave a Reply

© 2019 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS